CRISPR mediated MHC Depletion Service for Universal "Off-the-Shelf" CAR-T Exosome

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

The development of allogeneic CAR-T therapies is often hindered by significant challenges, including high manufacturing costs, risks of Graft-versus-Host Disease (GvHD), and the logistical complexities associated with patient-specific autologous products. Creative Biolabs' CRISPR-Mediated MHC Depletion service addresses these hurdles by enabling the production of universal "off-the-shelf" CAR-T exosomes derived from gene-edited donor cells. Through precision genomic engineering, we eliminate surface MHC molecules to create standardized, non-immunogenic exosome therapeutics that bypass stringent HLA-matching requirements. This approach allows us to transform complex cellular immunotherapies into scalable, ready-to-use biologic products, accelerating your pipeline while significantly reducing production time and complexity.

Introduction

By applying CRISPR to disrupt the beta-2-microglobulin (B2M) and class II major histocompatibility complex transactivator (CIITA) loci, we achieve stable MHC class I and II depletion, effectively rendering donor cells immunologically invisible to host T-cell recognition. This strategic MHC ablation, when combined with scalable exosome production from engineered CAR-T cells, facilitates the generation of universal, off-the-shelf nanovesicles that evade allogeneic immune detection while retaining potent, antigen-specific antitumor cytotoxicity, paving the way for readily accessible, standardized immunotherapies applicable across diverse patient populations.

Fig.1 CRISPR-engineered MHC-deficient exosomes for ready-to-use CAR-T immunotherapy. (Creative Biolabs Original) Fig.1 CRISPR-mediated elimination of MHC for off-the-shelf CAR-T extracellular vesicles.

CRISPR-Mediated MHC Depletion for Universal "Off-the-Shelf" CAR-T Exosomes at Creative Biolabs

Creative Biolabs provides a comprehensive solution for researchers seeking to transition from autologous to allogeneic therapeutic models. By utilizing CRISPR/Cas9 technology to knockout MHC class I and II molecules, we eliminate the primary triggers for immune rejection. This ensures that your CAR-T exosomes can be administered to any patient without the need for personalized manufacturing.

What We Can Offer

Creative Biolabs provides an integrated portfolio for developing universal off-the-shelf CAR-T exosomes, built upon a proprietary platform that combines multiplex gene editing, precision base modification, and non-viral knock-in technologies to engineer hypoimmunogenic producer cells capable of evading allorecognition while sustaining potent antitumor functionality within the tumor microenvironment.

Featured services of crispr-mediated MHC depletion for universal "off-the-shelf" CAR-T exosomes at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Sequence Data: Specific CAR construct sequences or desired antigen targets.
Donor Cells: Healthy donor-derived T cells or stabilized T-cell lines.
Payload Requirements: Information on specific miRNAs or small molecules to be loaded into the exosomes.

Key Steps:

Workflow of crispr-mediated MHC depletion for universal "off-the-shelf" CAR-T exosomes at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Purified Universal CAR-T Exosomes: High-titer, MHC-depleted vesicles in optimized storage buffers.
Comprehensive Analytical Report: Including MHC-knockout validation data, purity profiles, and potency assay results.

Key Advantages

True "Off-the-Shelf" Scalability: The creation of a stable, MHC-null CAR-T master cell line enables continuous, large-scale manufacturing of exosomes, eliminating the need for patient leukapheresis and bypassing the time constraints and costs associated with autologous therapies.
Enhanced Safety Profile: As acellular nanoparticles, these exosomes pose zero risk of insertional mutagenesis or uncontrolled proliferation, while the absence of cellular machinery completely abrogates the potential for Graft-versus-Host Disease (GvHD).
Superior Solid Tumor Penetration: The nanoscale size of exosomes facilitates superior biodistribution and penetration into the dense tumor microenvironment compared to whole CAR-T cells, potentially overcoming a major barrier in solid tumor immunotherapy.

FAQs

Q1: How do you ensure that CRISPR-mediated gene editing does not compromise exosome yield?

A1: Our optimized workflows preserve donor cell metabolic fitness throughout the engineering process. Following CRISPR modification, we quantitatively assess key exosome biogenesis markers to validate sustained secretory capacity, complemented by orthogonal QC assays confirming vesicle integrity and bioactivity remain fully intact.

Q2: Can these universal MHC-null exosomes serve as a platform for combinatorial drug delivery?

A2: Absolutely. Our technology enables dual-functional engineering: we can simultaneously modify the exosomal membrane for enhanced targeting while loading the lumen with synergistic therapeutic payloads. This includes but is not limited to chemotherapeutic agents or RNA-based inhibitors, facilitating potent combination regimens against refractory tumors.

Why Choose Us

Engage with Creative Biolabs at the forefront of two converging disciplines: CRISPR-based genetic engineering and exosome biology. As an integrated platform, we uniquely bridge advanced gene editing with scalable exosome manufacturing. By employing targeted MHC depletion, we engineer MHC-null vesicles that escape recognition by CD8+ T cells while preserving potent anti-tumor functionality across diverse HLA backgrounds.

Customer Reviews

"Integration of Creative Biolabs' CRISPR-based platform markedly enhanced the safety profile of our allogeneic exosome candidates, with rigorous orthogonal validation confirming robust ablation of B2M surface expression." Dr. H***y L.

"The exosome preparations demonstrated exceptional antigen-specific cytotoxicity, enabling our transition into solid tumor models where conventional CAR-T cells previously failed due to inadequate tumor infiltration." Prof. A***n S.

"The exhaustive analytical characterization provided proved pivotal for our IND submission. Creative Biolabs demonstrates an unparalleled understanding of exosome stability parameters and formulation requirements." M***a R.

How to contact us?

Creative Biolabs delivers a best-in-class platform that integrates precision CRISPR-mediated MHC depletion with advanced exosome manufacturing. Our proprietary workflow enables the engineering of universal, off-the-shelf CAR-T exosomes designed to bypass allogeneic immune detection while retaining potent antitumor activity. By merging cutting-edge gene editing with scalable vesicle purification, we address critical translational challenges in oncology, including immune antigenicity and production scalability. We welcome inquiries for collaborative research or customized service development—please visit our website to connect with our scientific team and initiate a consultation.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.